Patents by Inventor John Cunningham O'Toole

John Cunningham O'Toole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8680091
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Karen Briner, Manuel Javier Cases-Thomas, Marta Adeva Bartolome, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O'Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
  • 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    Publication number: 20110269745
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: June 9, 2011
    Publication date: November 3, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Karin BRINER, Marta ADEVA BARTOLOME, Manuel Javier CASES-THOMAS, Christopher Stanley GALKA, Alicia MARCOS LLORENTE, Maria Angeles MARTINEZ-GRAU, Michael Philip MAZANETZ, John Cunningham O'Toole, Richard Edmund RATHMELL, Matthew Robert REINHARD, Selma SAPMAZ, Andrew Caerwyn WILLIAMS
  • 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
    Publication number: 20080269196
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: October 30, 2008
    Inventors: Karin Briner, Maria Adeva Bartolome, Manuel Javier Cases-Thomas, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O' Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
  • Arylpiperazines having activity at the serotonin 1receptor
    Patent number: 7309702
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: December 18, 2007
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang, Jeffrey Forrester McKelvy
  • Arylpiperazines having activity at the serotonin 1A receptor
    Patent number: 7001908
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: February 21, 2006
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Arylpiperazines having activity at the serotonin 1A receptor
    Patent number: 6946579
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: September 20, 2005
    Assignee: Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Arylpiperazines having activity at the serotonin 1A receptor
    Publication number: 20040049083
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: July 2, 2003
    Publication date: March 11, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Arylpiperazines having activity at the serotonin 1A receptor
    Publication number: 20040044009
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: April 16, 2003
    Publication date: March 4, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Arylpiperazines having activity at the serotonin 1A receptor
    Publication number: 20020169170
    Abstract: A method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, comprising administering to a patient in need of such treatment a serotonin reuptake inhibitor in combination with an effective amount of a compound of the formula 1
    Type: Application
    Filed: December 18, 2001
    Publication date: November 14, 2002
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O' Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Arylpiperazines having activity at the serotonin 1A receptor
    Publication number: 20010003749
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: January 3, 2001
    Publication date: June 14, 2001
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang